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Targets and self monitoring in hypertension: randomised controlled
trial and cost effectiveness analysis
R J McManus, J Mant, A Roalfe, R A Oakes, S Bryan, H M Pattison, F D R Hobbs
Abstract
Objectives To assess whether blood pressure control in
primary care could be improved with the use of patient held
targets and self monitoring in a practice setting, and to assess
the impact of these on health behaviours, anxiety, prescribed
antihypertensive drugs, patients’ preferences, and costs.
Design Randomised controlled trial.
Setting Eight general practices in south Birmingham.
Participants 441 people receiving treatment in primary care
for hypertension but not controlled below the target of
< 140/85 mm Hg.
Interventions Patients in the intervention group received
treatment targets along with facilities to measure their own
blood pressure at their general practice; they were also asked to
visit their general practitioner or practice nurse if their blood
pressure was repeatedly above the target level. Patients in the
control group received usual care (blood pressure monitoring
by their practice).
Main outcome measures Primary outcome: change in systolic
blood pressure at six months and one year in both intervention
and control groups. Secondary outcomes: change in health
behaviours, anxiety, prescribed antihypertensive drugs, patients’
preferences of method of blood pressure monitoring, and costs.
Results 400 (91%) patients attended follow up at one year.
Systolic blood pressure in the intervention group had
significantly reduced after six months (mean difference 4.3 mm
Hg (95% confidence interval 0.8 mm Hg to 7.9 mm Hg)) but not
after one year (mean difference 2.7 mm Hg ( − 1.2 mm Hg to 6.6
mm Hg)). No overall difference was found in diastolic blood
pressure, anxiety, health behaviours, or number of prescribed
drugs. Patients who self monitored lost more weight than
controls (as evidenced by a drop in body mass index), rated self
monitoring above monitoring by a doctor or nurse, and
consulted less often. Overall, self monitoring did not cost
significantly more than usual care (£251 ($437; 364 euros) (95%
confidence interval £233 to £275) versus £240 (£217 to £263).
Conclusions Practice based self monitoring resulted in small
but significant improvements of blood pressure at six months,
which were not sustained after a year. Self monitoring was well
received by patients, anxiety did not increase, and there was no
appreciable additional cost. Practice based self monitoring is
feasible and results in blood pressure control that is similar to
that in usual care.
Introduction
Hypertension is a key risk factor for cardiovascular disease, the
leading cause of death worldwide.1 Use of antihypertensive drugs
leads to a significant reduction in both stroke and coronary heart
disease risk and is cost effective, especially for individuals at
highest risk of cardiovascular events.2 3 This potential benefit
from drug treatment is reflected in recent hypertension
guidelines, which recommend treatment targets of 140/85 mm
Hg or below.4 5 However, international community based surveys
show that in many countries only a minority of people treated
for hypertension are controlled to these levels.6
Most patients with hypertension receive treatment in
primary care and so it is here that potential reasons for this
shortfall must be sought. These may include clinical inertia and
excessive workloads on the part of physicians7 8; unmet informa-
tion needs and poor adherence to antihypertensive treatment by
patients9 10; and differing thresholds at which health profession-
als and patients would choose to start treatment.11
Self monitoring of blood pressure has the potential to
improve blood pressure control at modest cost: a recent system-
atic review of home monitoring found a lowering of systolic
blood pressure of about 4 mm Hg.12 However, most included tri-
als were inadequately powered with short (six months or less)
follow-up, none was performed in the United Kingdom, and only
one study evaluated costs.13 Community based self monitoring,
where patients have access to blood pressure measurement
facilities without the need to see a health professional, has the
potential to provide the benefits of home monitoring (reduction
of the white coat effect, more readings, and improved control)
without requiring the purchase of a blood pressure machine for
all patients.14 15
We aimed to assess whether blood pressure control in
primary care could be improved with the use of patient held tar-
gets and self monitoring in a practice setting and to assess the
impact of these on health behaviours, anxiety, prescribed antihy-
pertensive treatment, patients’ preferences, and costs.
Methods
Participants
We recruited participants from eight primary care practices in
Birmingham through the Midlands Research Practice Consor-
tium between September 2001 and April 2002. The practices
were selected so that there would be two from each quartile of
the Townsend score (a measure of socioeconomic deprivation).16
A computer search identified patients aged 35-75 receiving
treatment for hypertension. Those with at least one blood pres-
sure reading greater than 140/85 mm Hg in the previous year
were invited to attend a study clinic run by the principal investi-
gator (RJMcM). If their blood pressure at this clinic was in the
range 140/85 mm Hg to 200/100 mm Hg they were eligible for
the study. All patients provided written informed consent before
entry to the study.
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Assignment and blinding
Randomisation was stratified by practice and diabetic status; we
used a random number generator to produce a series of blocks
of random size.17 Allocations were transferred to opaque
envelopes that were held centrally and opened by the trial secre-
tary in response to a telephone call. In one practice, owing to an
error in the blocking process, three people with diabetes were
allocated to the control rather than intervention group. The
study was unblinded.
Intervention
Patients randomised to intervention were asked to attend their
practice every month to measure their own blood pressure using
validated electronic blood pressure machines (Omron M5-I18).
They did not need an appointment, and they did the monitoring
in the waiting room or in a side room, depending on facilities at
the practice. They were given about 10 minutes of instruction at
baseline on how to use the electronic sphygmomanometers and
a five minute refresher session at a six month follow-up. Recep-
tion staff were also trained to provide support to patients as
required.
The patients in the intervention group each received a
record card showing the blood pressure target they should aim
for (the British Hypertension Society’s treatment targets—at that
time—of 140/85 mmHg (140/80 mm Hg for those with
diabetes)).4 19 The cards had space for recording monthly blood
pressure readings as well as advice that patients should attend
their general practitioner or practice nurse if they recorded
blood pressures above target on successive months—or earlier in
the case of very high readings. Central telephone support was
available.
Frequency of monitoring of patients in the control group was
at the discretion of the general practitioner. All control patients
received an information sheet on self help measures to lower
blood pressure based on a fact sheet published by the British
Hypertension Society (www.bhsoc.org). Responsibility for
changes to treatment remained with the general practitioner for
both the intervention and control group.
Data collection
All baseline data and measurements were recorded before
randomisation. Patients were followed up by a researcher
(RJMcM or RAO) in their own surgeries six months and one year
after randomisation. All primary and secondary end point data
were collected at each follow-up visit.
At follow-up sessions, blood pressure was measured with a
validated automated sphygmomanometer (Omron 705CP) in
the left arm three times at five minute intervals after 10 minutes
rest, with the patient seated. We used the mean of the three read-
ings in the analysis.We measured anxiety using the short form of
the Spielberger state anxiety inventory20 and used previously
validated questionnaires for alcohol consumption21 and exer-
cise22 to measure lifestyle factors. We assessed addition of salt to
food by using questions drawn from a validated questionnaire.23
We calculated body mass index using electronic scales (Seca 880,
Vogel and Halke, Hamburg) and a portable height meter. At
each follow up visit we collected data on prescribed
antihypertensive drugs from the practice computer systems. We
asked participants to rank four methods of blood pressure meas-
urement according to preference—namely, by a doctor, by a
nurse, self measurement at the surgery, and self measurement at
home.
Analysis
The primary outcome was change in systolic blood pressure
between baseline and the two follow-up sessions. A power calcu-
lation suggested that if 434 patients were followed up, it would be
possible to detect a 5 mmHg difference with a power of 90% and
significance level of 5%, assuming a standard deviation of 16 mm
Hg. We analysed the data with the statistical software SPSS (ver-
sion 10) on an “intention to treat” basis using the “complete case”
method with sensitivity analysis around assumptions for missing
values.24 We used the GLM (general linear model) repeated
measures technique to examine within subject differences in
systolic blood pressure between baseline and the two follow-up
sessions. We adjusted the primary analysis for practice (nested
within intervention) and diabetic status by including these as
fixed effects in the model along with any baseline differences
with potential effects on outcome.
We also used the GLM repeated measures technique for the
secondary outcomes—to analyse changes in diastolic blood pres-
sure, anxiety, body mass index, and patients’ preferences.
Changes over time between intervention and control with
respect to exercise (three times or more a week), alcohol ( > 21 or
> 14 units a week for men and woman respectively), smoking
(yes or no), and addition of salt to food were assessed using logis-
tic regression, taking into account repeated measures and adjust-
ing for practice, diabetic status, and sex.
Costing
During the trial we collected data on the number of
consultations for hypertension (with both general practitioners
and practice nurses and defined as consultations with Read
codes for hypertension or where blood pressure was recorded or
where free text explicitly mentioning hypertension management
was included), drug treatment, referrals for hypertension, and
intervention costs (for equipment and training). Equipment costs
were discounted at 3.5% (a year) over a five year life.25 We
assumed that consultations had standard UK costs (£16 ($28;
€23) for a general practitioner and £8 for a practice nurse)26; we
took treatment costs from the British National Formulary27; and
we priced referrals at the rate for a general medical outpatient
clinic (£104).28 Cost data were bootstrapped (1000 samples) to
estimate confidence intervals.
Results
In all, 441 people were randomised, of whom 400 (91%)
attended follow-up at both six and 12 months (complete cases).
The figure shows flow through the trial, and table 1 shows base-
line details of complete cases. In all, 74% of participants in the
intervention group measured their own blood pressure at least
eight times over 12 months (prespecified as the definition of
adequate compliance), and the median number of self measure-
ments over a year was 11. Owing to the baseline difference in sex
and the potential effect on outcome, sex was included in the
model as prespecified in the analysis plan.
Primary outcome (systolic blood pressure)
The GLM repeated measures—taking into account intervention
group, practice (nested within intervention), sex, and diabetic
status—showed a significant difference in systolic blood pressure
over time between intervention and control (F (2, 762) = 3.7;
P = 0.02). Further analysis of this change in systolic blood
pressure showed a significant difference between groups in
favour of the intervention between baseline and six month
follow-up (mean difference in change 4.3 mm Hg (95%
confidence interval 0.8 mm Hg to 7.9 mm Hg); F (1, 381) = 8.2;
Primary care
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P = 0.004) but not between six months and one year ( − 1.6 mm
Hg ( − 5.3 mm Hg to 2.2 mm Hg); F (1, 381) = 1.0; P = 0.33)
(table 2). The intervention group experienced a greater fall in
blood pressure in the first six months, but from a higher baseline.
Mean systolic blood pressure at six and 12 months was similar in
the two groups.
Secondary outcomes
Diastolic pressure did not change significantly over time between
the groups (F (1.9, 737.9) = 0.08; P = 0.91) (fractional degrees of
freedom result from adjustments made when Mauchly’s test for
sphericity was significant) (table 2). The groups did not differ
over time for anxiety, smoking, exercise, salt intake, or number of
prescribed drugs (tables 3 and 4). Body mass index reduced sig-
nificantly more over time in the intervention group than in the
control group (F (1.6, 590.9) = 6.010; P = 0.005). Most of the
reduction occurred in the first six months of the study: with the
repeated measures comparisons, the change between baseline
and six months is significant (F (1, 370) = 10.3; P = 0.001)
whereas that between six months and one year is not (F (1, 370)
= 0.58; P = 0.45). Reported alcohol intake reduced significantly
in the intervention group compared with the control group in
the first six months but not thereafter (P = 0.03 and P = 0.56
respectively).
Table 5 shows patients’ preferences at the end of the study for
method of blood pressure measurement. The ranking was
significantly different between the intervention and control
groups (F (2.1, 820.5) = 37.4; P < 0.001). Patients in the
intervention group ranked home measurement highest,
followed by self measurement in the surgery. Those in the
control group ranked measurement by a doctor highest,
followed by nurse measurement.
Sensitivity analysis
Missing values analysis on the primary outcome of systolic blood
pressure found that for substitution of missing values by either
the mean of the series or by the last recorded value for an indi-
vidual, the change in systolic blood pressure in the first six
months remained significant (P = 0.03 in both cases), but the
overall difference between the groups over time was no longer
significant (P = 0.11 (substitution by mean of series) and P = 0.10
(substitution by last recorded value)).
Cost effectiveness
Table 6 shows the cost and effectiveness results. The intervention
group consulted less frequently than the control group, and the
drug costs did not differ significantly between the two groups.
The reduction in consultation rate observed in the intervention
group reflected fewer consultations in which blood pressure
monitoring alone took place. Intervention costs (£26.80 per
patient) were dominated by the cost of general practitioners’
time in training staff and patients (£25.40), with discounted
equipment costs relatively trivial (£1.39). The incremental cost
effectiveness ratio for practice based self monitoring—that is, the
cost per additional 1 mm Hg reduction in blood pressure—was
£5.10, with confidence intervals that crossed zero (table 5).
Discussion
In this study, giving patients their own blood pressure targets and
encouraging them to monitor their own blood pressure resulted
in a significant reduction in blood pressure at six month
follow-up but not thereafter, compared with patients whose
monitoring was left to the discretion of their practice. Self moni-
toring did not increase anxiety, and patients in the intervention
group ranked this method more highly than monitoring by the
general practitioner or nurse (in contrast to the control group).
Aged 35-75 with hypertension (n=3543)
Invited (n=2057)
Had blood pressure <140/85  in past year (n=1376)
Excluded by general practitioner (n=110):
  General practitioner felt inappropriate (n=77)
  Housebound (n=23)
  Terminally ill (n=4)
  Other (n=6)
Attended initial clinic (n=559)
Declined invitation (n=1498)
Did not attend follow-up
 at 6 months (n=10)
Randomised (n=441)
Intervention (n=214)Control (n=227)
Attended follow-up
 at 6 months (n=217)
Did not attend follow-up
 at 12 months (n=6)
* Two controls did not attend follow-up at 6 months but
    attended follow-up at 12 months (400 complete cases)
Attended follow-up
 at 12 months (n=213)*
Did not attend follow-up
 at 6 months (n=17)
Attended follow-up
 at 6 months (n=197)
Did not attend follow-up
 at 12 months (n=8)
Attended follow-up
 at 12 months (n=189)
Had blood pressure outside inclusion range (n=103)
Declined after explanation (n=15)
Flow of participants through the trial
Table 1 Baseline characteristics of 400 complete cases (unadjusted). Values
are numbers (percentages) of participants, unless stated otherwise
Attribute
Intervention
(n=189)
Control
(n=211)
Mean (SD) age (years) 62.8 (8.5) 62.4 (9.9)
Male 98 (52) 90 (43)
Mean (SD) systolic blood pressure (mm Hg) 157.9 (15.7) 155.0 (13.6)
Mean (SD) diastolic blood pressure (mm Hg) 88.7 (7.3) 88.0 (7.9)
Ethnic group*:
White 180 (95) 195 (92)
Black or Black British 7 (4) 13 (6)
Asian or Asian British 2 (1) 3 (1)
Mean (SD) body mass index (kg/m2) 30.5 (5.3) 29.5 (5.5)
Current smokers 23 (12) 24 (11)
Men drinking >21 or women >14 units of alcohol a week 28 (15) 14 (7)
Exercise ≥3 times/week 52 (28) 53 (25)
Mean (SD) anxiety score† 9.8 (3.0) 9.3 (3.0)
History of coronary heart disease 31 (16) 27 (13)
History of diabetes 25 (13) 34 (16)
Mean (SD) No of antihypertensive drugs 1.8 (0.9) 1.9 (0.9)
Currently working 51 (27) 61 (29)
*According to 2001 United Kingdom census criteria. White includes White British or White
Other. Black or Black British includes those of Caribbean, African, or Black Other ethnicity.
Asian or Asian British includes those of Indian, Pakistani, Bangladeshi or Asian Other ethnicity
(see www.statistics.gov.uk/census2001/census2001.asp).
†On the state trait anxiety inventory (scores range from 6 to 24: the higher the score, the
higher the anxiety).
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Costs of self monitoring were not significantly greater than usual
care as equipment costs were trivial and the additional time
required for training patients in self monitoring was balanced by
a reduced consultation rate.
Body mass index was significantly reduced in the
intervention group, suggesting a mechanism of blood pressure
reduction through a healthier lifestyle. Of the health related
behaviours examined, only alcohol intake changed significantly
between the two groups (in the first six months only).
Possible biases
That the study was unblinded will have had minimal effect on the
primary outcome as blood pressure was recorded in a standard-
ised fashion by a single individual using a print-out of an
automated sphygmomanometer. However, greater familiarity
with automated sphygmomanometers in patients in the
intervention group might have led to a reduced “white coat”
effect at follow-up, thereby causing an artefactually greater
reduction in blood pressure in the intervention group.
The study used individual rather than cluster randomisation,
so there is a possibility of “contamination” of the control group,
in that blood pressure monitors were available in the waiting
room. However, all participants were asked whether they had
monitored their blood pressure on additional occasions (that is,
outside the requirements of the study), and we found no
evidence that control patients had done so (data available on
request). We failed to obtain complete follow-up data for 41 (9%)
participants, but sensitivity analysis indicated that this is unlikely
to have had an important effect on the results.
The intervention was of relatively low intensity. More
frequent measurement of blood pressure, particularly in the ini-
tial phases of adjustment of drug treatment, might have led to
better blood pressure control.Monthly measurement was chosen
as being frequent enough to allow action based on readings
within an appropriate timescale while not being too onerous for
patients. The latter was important given the aim of studying self
measurement of blood pressure in a community setting rather
than at home.
In adopting a health service perspective, we did not take into
account additional patient costs. A recent analysis suggested that
an average attendance at a primary care centre costs about £5
and therefore if individuals were to measure their own blood
pressure at their practice on eight occasions annually this would
have a notional cost for each individual of £40.29 Given that the
automated sphygmomanometers used in the study now cost
around £50 and might be expected to have a useful life of five
Table 3 Secondary outcomes: anxiety, body mass index, and number of prescribed medications
Unadjusted Adjusted*
Adjusted mean difference (95% confidence
interval)*†
Baseline 6 months 12 months Baseline 6 months 12 months Baseline to 6 months Baseline to 12 months
State anxiety inventory score‡
Intervention 9.8 9.6 9.5 10.0 9.7 9.6 0.4 (−0.3 to 1.1) 0.3 (−0.4 to 0.9)
Control 9.3 9.3 9.1 9.2 9.3 9.1
Body mass index
Intervention 30.5 30.1 30.2 31.8 31.1 31.3 0.7 (0.3 to 1.1) 0.6 (0.1 to 1.1)
Control 29.5 29.4 29.4 29.9 30.0 30.0
No of prescribed drugs
Intervention 1.8 2.0 2.0 1.9 2.0 2.0 0.0 (−0.2 to 0.1) −0.1 (−0.2 to 0.1)
Control 1.9 2.0 2.0 2.0 2.1 2.1
*Adjusted for practice (nested within intervention), diabetic status, and sex.
†Difference between change in intervention outcome and change in control. Positive values show greater change in intervention.
‡Scores range from 6 to 24 (the higher the score, the higher the anxiety).
Table 2 Mean systolic and diastolic blood pressure (mm Hg)
Unadjusted Adjusted*
Adjusted mean difference (95% confidence
interval) *†
Baseline 6 months 12 months Baseline 6 months 12 months Baseline to 6 months Baseline to 12 months
Systolic (mm Hg)
Intervention 157.9 144.5 149.0 159.3 144.5 149.5 4.3 (0.8 to 7.9) 2.7 (−1.2 to 6.6)
Control 155.0 144.7 148.4 156.1 145.6 149.0
Diastolic (mm Hg)
Intervention 88.7 83.2 83.0 87.4 82.4 82.1 −0.4 (−2.4 to 1.7) 0.1 (−2.3 to 2.4)
Control 88.0 83.3 83.4 86.6 81.3 81.5
*Adjusted for practice (nested within intervention), diabetic status, and sex.
†Difference between change in intervention blood pressure and change in control blood pressure. Positive values show greater change in intervention.
Table 4 Secondary outcomes: health behaviour. Values are numbers
(percentages) of participants, unless stated otherwise
Baseline 6 months 12 months
P value for change
Baseline to
6 months
Baseline to
12 months
Exercise*
Intervention 51 (28) 69 (37) 59 (32) 0.53 0.49
Control 53 (25) 80 (38) 59 (28)
Salt†
Intervention 152 (80) 148 (78) 136 (72) 0.82 0.11
Control 170 (81) 167 (79) 164 (78)
Alcohol‡
Intervention 28 (15) 21 (11) 17 (9) 0.03 0.56
Control 15 (7) 21 (10) 10 (5)
Smoking§
Intervention 23 (12) 25 (13) 27 (14) 0.10 0.50
Control 24 (11) 20 (9) 22 (10)
For all health behaviours except exercise, n=189 (intervention) and 211 (control); for exercise,
owing to missing values, n=185 (intervention) and 208 (control).
All patients were advised to exercise at least three times a week, stop adding salt to food,
drink less than 21 (males) or 14 (females) units of alcohol and stop smoking if they were
smokers.
*Exercising ≥3 times a week. †Adding salt to food or cooking. ‡Drinking >21 (men) or 14
(women) units a week. §Smoking ≥1 cigarette a day.
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years, if a societal perspective were taken, then patients might
reasonably request home monitoring rather than the centralised
model used in this study.
Comparison with other studies
We believe this study to be the first randomised controlled trial in
the United Kingdom to evaluate the effect of self monitoring of
hypertension and the first randomised controlled trial anywhere
to use a community clinic setting for self measurement. Cappuc-
cio and colleagues in a recent systematic review identified 18
randomised controlled trials involving self monitoring at home.12
This meta-analysis found reductions in systolic blood pressure of
4.2 mm Hg (95% confidence interval 1.5 mm Hg to 6.9 mm Hg)
and in diastolic blood pressure of 2.4 mm Hg (1.2 mm Hg to 3.5
mm Hg). However, only one of the studies included self monitor-
ing over 12 months or more with sufficient participants to detect
changes in blood pressure of the size found in the meta-analysis:
Soghikian and colleagues studied 430 people with uncompli-
cated hypertension who monitored their own blood pressure at
home for a year in the setting of the Kaiser Permanente medical
care programme.13 They found that blood pressure control was
similar for self monitoring and usual care and that overall costs
were similar too; savings were apparent in terms of consultations
and laboratory tests associated with hypertensive care, which
cancelled out the increased costs of monitoring. Other studies of
self monitoring are not comparable with our study owing to
small size, use of manual rather than automated self monitoring
equipment, or use of extensive cointerventions.12
Little and colleagues in the United Kingdom have evaluated
the acceptability to patients of measuring their own blood pres-
sure both at home and in a surgery setting.30 In that study, blood
pressure was measured in various settings and included self
measurement; the participants ranked home monitoring as
more acceptable than other methods of blood pressure
measurement—which we also found in the intervention group in
our study. The control participants in our study, however,
preferred measurement by a doctor or nurse, and so our results
suggest that experience of self monitoring influences patients’
views. Given the relatively low proportion (27%) of potentially
eligible subjects responding to the study invitation, more success
in recruiting individuals to self monitoring may require “taster”
sessions to allow people to see what they are letting themselves in
for.
Conclusion
Blood pressure can be controlled to the same degree with either
practice based self monitoring or usual care. This confirms that
community based self monitoring has the potential to bring the
benefits of home monitoring to individuals without the means to
purchase their own equipment. Self monitoring of blood
pressure results in worthwhile and significant improvements in
systolic blood pressure at six months. How this early
improvement might be maintained requires further study. Self
monitoring has negligible costs, reduces practice consulting
rates, is acceptable to (and preferred by) patients and does not
increase anxiety. If the training associated with self monitoring
were performed by non-medical or lay individuals then cost sav-
ings might be possible. In an average practice, a few practice
based automated sphygmomanometers would be sufficient for
the hypertensive population. General practitioners should offer
this option to their hypertensive patients.
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Table 5 Patients’ ranking of methods of blood pressure measurement at
end of study*
Doctor Nurse
Self measurement
at home
Self measurement
in surgery
Intervention group
Mean ranking 2.59 2.56 1.98 2.46
Median ranking
(interquartile range)
3 (1-4) 3 (2-3) 1 (1-3) 2 (2-3)
Control group
Mean ranking 1.91 1.96 2.71 3.07
Median ranking
(interquartile range)
2 (1-3) 2 (1-2) 3 (1-4) 3 (3-4)
The two participants who did not attend the first follow-up but attended the second, are
included in this analysis.
*Methods were ranked 1 to 4 (1=prefer most, 4=prefer least).
Table 6 Costs and effects of self monitoring compared with usual care
(adjusted effects). Values are per patient per year (95% confidence interval)
Practice based
self monitoring
Control
(usual care)
Mean No of consultations for hypertension 3.6 (3.2 to 4.0) 4.4 (4.0 to 4.9)
Mean drug costs for hypertension (£) 174 (162 to 189)* 180 (164 to 196)*
Intervention costs (£) 27
Mean cost (£) 251 (233 to 275)* 240 (217 to 263)*
Mean effect (mm Hg) 9.9 (5.8 to 13.9) 7.1 (3.4 to 10.8)
Mean incremental cost effectiveness
ratio(£/mm Hg)
5.1 (−7.2 to 19.1)*
*Boot strapped confidence intervals.
What is already known on this topic
Home monitoring by hypertensive patients results in small
but significant reductions in blood pressure, though the
studies with such findings have largely been underpowered
with inadequate length of follow up
No published randomised studies have evaluated self
monitoring outside the home
What this study adds
Small early reductions of blood pressure are achieved by
self monitoring in a community setting, but these are not
maintained long term
The reductions seem to result from non-pharmacological
mechanisms rather than more intensive treatment
Self monitoring is feasible in a community setting, highly
acceptable to hypertensive patients, and cost effective in the
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